Clinical Trial: REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07834372) titled 'REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease' on Sept. 11.

Brief Summary: REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in which participants receive the unblinded results of Heartflow AI-CPA or the usual care arm in which participants are blinded to the AI-CPA results.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: CAD - Coronary Arte...